ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Outcomes after Immunosuppressive Therapy for Aplastic Anemia: A Single Centre Experience from Northern India.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Aplastic anemia (AA) in children is a life-threatening disorder with very few therapeutic options. This study was carried out to assess the response of Immunosuppressive therapy (IST) in children with non-inherited AA. Methods: It was a prospective observational study carried out among 35 children aged less than 18 years, recently diagnosed with AA by bone marrow biopsy. Those suffering from inherited bone marrow failure syndromes and secondary AA were excluded. IST included equine anti-thymocyte globulin (eATG), steroids, and cyclosporine. Response to immunosuppressive therapy was assessed after four months. Results: The mean age was 10.77 ± 3.6 years. Non-severe AA was diagnosed in 65.71% of children with severe and very severe AA in 17.14%. The overall response rate was found to be 65.7%, with 54.28% of children achieving a partial response and 11.42% of children achieving a complete response. Whereas 17.14% did not respond to treatment, and another 17.14% of children expired before the time point of response assessment. Hemoglobin levels, total leucocyte count, platelet count, and reticulocyte count showed statistically significant elevation following IST. Conclusion: IST can be safely and effectively used as the first-line treatment option in children with non-inherited aplastic anemia, especially when stem cell transplant is not a feasible option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.